MXPA04001125A - Composicion de vacuna que comprende al menos dos valencias, una mejorada con adyuvante y la otra no. - Google Patents
Composicion de vacuna que comprende al menos dos valencias, una mejorada con adyuvante y la otra no.Info
- Publication number
- MXPA04001125A MXPA04001125A MXPA04001125A MXPA04001125A MXPA04001125A MX PA04001125 A MXPA04001125 A MX PA04001125A MX PA04001125 A MXPA04001125 A MX PA04001125A MX PA04001125 A MXPA04001125 A MX PA04001125A MX PA04001125 A MXPA04001125 A MX PA04001125A
- Authority
- MX
- Mexico
- Prior art keywords
- valence
- vaccine composition
- valences
- adjuvant
- enhanced
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invencion se relaciona a una composicion de vacuna, que comprende dos valencias; (i) una primera valencia la cual es adyuvante-mejorada con hidroxido de aluminio e (ii) una segunda valencia la cual contiene un polisacarido de capsula bacterial que comprende uno o mas grupos O-acetilo, y en los cuales no se adsorbe con oxido de aluminio debido a la presencia de un compuesto protector el cual puede ser un fosfato, un citrato o un carbonato y el cual evita tal adsorcion. La primera valencia puede ser cualquier valencia de vacuna. En una modalidad particular, la composicion de vacuna contiene (i) la valencia de Hepatitis A, adsorbida en hidroxido de aluminio e (ii) la valencia de fiebre tifoidea formada por el polisacarido Vi de la capsula de Salmonella tyhpi.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0110573A FR2828406B1 (fr) | 2001-08-08 | 2001-08-08 | Composition vaccinale bivalente havi |
PCT/FR2002/002770 WO2003013600A1 (fr) | 2001-08-08 | 2002-07-31 | Composition vaccinale comprenant au moins deux valances, l'une adjuvantee, l'autre pas |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04001125A true MXPA04001125A (es) | 2004-05-20 |
Family
ID=8866367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04001125A MXPA04001125A (es) | 2001-08-08 | 2002-07-31 | Composicion de vacuna que comprende al menos dos valencias, una mejorada con adyuvante y la otra no. |
Country Status (22)
Country | Link |
---|---|
US (1) | US7404960B2 (es) |
EP (1) | EP1416958B2 (es) |
JP (1) | JP4221291B2 (es) |
KR (1) | KR100881703B1 (es) |
CN (1) | CN1282486C (es) |
AT (1) | ATE357929T1 (es) |
AU (1) | AU2002342949B2 (es) |
BR (1) | BRPI0211151B8 (es) |
CA (1) | CA2455406C (es) |
CY (1) | CY1107619T1 (es) |
DE (1) | DE60219177T3 (es) |
DK (1) | DK1416958T4 (es) |
ES (1) | ES2284940T5 (es) |
FR (1) | FR2828406B1 (es) |
HU (1) | HU228216B1 (es) |
IL (2) | IL159519A0 (es) |
MX (1) | MXPA04001125A (es) |
NZ (1) | NZ530727A (es) |
PL (1) | PL215134B1 (es) |
PT (1) | PT1416958E (es) |
WO (1) | WO2003013600A1 (es) |
ZA (1) | ZA200400022B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2464522C (en) | 2004-04-15 | 2011-11-15 | Eng-Hong Lee | Soft gel delivery system for treating poultry |
BRPI0716518B8 (pt) * | 2006-09-07 | 2021-05-25 | Glaxosmithkline Biologicals Sa | vacina de ipv e uso da mesma |
KR101101901B1 (ko) * | 2009-01-30 | 2012-01-02 | 주식회사 리노 | 주방용 선반 |
PT2411048T (pt) | 2009-03-24 | 2020-07-14 | Glaxosmithkline Biologicals Sa | Proteína de ligação ao fator h meningocócica com adjuvante |
CN102526724B (zh) * | 2011-01-14 | 2015-07-22 | 四川大学 | 氢氧化铝凝胶-多糖复合免疫佐剂及其制备方法和用途 |
FR2985663B1 (fr) * | 2012-01-17 | 2015-03-27 | Sanofi Pasteur | Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2734484B1 (fr) * | 1995-05-24 | 1997-06-27 | Pasteur Merieux Serums Vacc | Composition vaccinale liquide et procede de fabrication |
GB9806456D0 (en) * | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
EP1285666A1 (en) * | 1998-08-28 | 2003-02-26 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Salmonella typhi vaccine compositions |
US6585973B1 (en) * | 1998-10-29 | 2003-07-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method for preparing solid phase conjugated vaccine |
GB9909077D0 (en) * | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
-
2001
- 2001-08-08 FR FR0110573A patent/FR2828406B1/fr not_active Expired - Lifetime
-
2002
- 2002-07-31 KR KR1020047001923A patent/KR100881703B1/ko active IP Right Grant
- 2002-07-31 MX MXPA04001125A patent/MXPA04001125A/es active IP Right Grant
- 2002-07-31 PL PL367904A patent/PL215134B1/pl unknown
- 2002-07-31 AU AU2002342949A patent/AU2002342949B2/en not_active Expired
- 2002-07-31 NZ NZ530727A patent/NZ530727A/en not_active IP Right Cessation
- 2002-07-31 JP JP2003518604A patent/JP4221291B2/ja not_active Expired - Lifetime
- 2002-07-31 PT PT02779603T patent/PT1416958E/pt unknown
- 2002-07-31 US US10/485,748 patent/US7404960B2/en not_active Expired - Lifetime
- 2002-07-31 ES ES02779603T patent/ES2284940T5/es not_active Expired - Lifetime
- 2002-07-31 EP EP02779603A patent/EP1416958B2/fr not_active Expired - Lifetime
- 2002-07-31 BR BRPI0211151-9 patent/BRPI0211151B8/pt not_active IP Right Cessation
- 2002-07-31 DK DK02779603.6T patent/DK1416958T4/da active
- 2002-07-31 AT AT02779603T patent/ATE357929T1/de active
- 2002-07-31 IL IL15951902A patent/IL159519A0/xx unknown
- 2002-07-31 HU HU0401182A patent/HU228216B1/hu unknown
- 2002-07-31 DE DE60219177T patent/DE60219177T3/de not_active Expired - Lifetime
- 2002-07-31 CN CNB028156455A patent/CN1282486C/zh not_active Expired - Lifetime
- 2002-07-31 CA CA2455406A patent/CA2455406C/en not_active Expired - Lifetime
- 2002-07-31 WO PCT/FR2002/002770 patent/WO2003013600A1/fr active IP Right Grant
-
2003
- 2003-12-22 IL IL159519A patent/IL159519A/en unknown
-
2004
- 2004-01-05 ZA ZA200400022A patent/ZA200400022B/en unknown
-
2007
- 2007-04-16 CY CY20071100521T patent/CY1107619T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2534625A1 (en) | Infection prophylaxis using immune response modifier compounds | |
ATE322287T1 (de) | Solubisierung von kapseln polysacchariden | |
PT777490E (pt) | Enterotoxina mutante eficaz como adjuvante oral nao toxico | |
SE0102315D0 (sv) | Compounds | |
AU2001278003A1 (en) | Bacteriophage having multiple host range | |
CA2096529A1 (en) | Recombinant avirulent salmonella antifertility vaccines | |
MXPA04001125A (es) | Composicion de vacuna que comprende al menos dos valencias, una mejorada con adyuvante y la otra no. | |
DE60225349D1 (de) | Immunstimulierende und regulierende zusammensetzung mit bakteriellen chromosomalen dna-fragmenten und nichttoxischen lipopolysacchariden | |
ATE355853T1 (de) | Heterologer schutz, induziert durch immunisierung mit der invaplex-vakzine | |
TW200515917A (en) | Methods and compositions for the generation of a protective immune response against SARS-COV | |
EP0810283A3 (en) | Live attenuated RTX-procucing bacteria of the family Pasteurellaceae | |
BR0114403A (pt) | Polipeptìdeos de "haemophilus influenzae" que podem ser usados para fins de profilaxia, diagnóstico e/ou terapia | |
MX9704061A (es) | Bacterias productoras de rtx atenuadas vivas de la familia pasteurellaceae. | |
AU2002342949A1 (en) | Vaccine composition comprising at least two valences, one with enhanced adjuvant and not the other | |
WO2002045738A3 (es) | Composicion vacunal que contiene factor de crecimiento transformante alfa | |
EA200200704A1 (ru) | Ослабленные микроорганизмы для лечения инфекции | |
Feterl et al. | Supplementary materials: The epidemiology of malaria in Kutubu, Southern Highlands Province, Papua New Guinea, before and during a private sector initiative for malaria control | |
Howard | The Host of Dreams | |
RU98110352A (ru) | Шихта для получения водоустойчивого известкового клинкера | |
ITVA20020058A1 (it) | Composizioni di pvc stabili al calore. | |
FI864769A (fi) | Icke-adjuvanserad vaccin. | |
JP2003144089A5 (es) | ||
RU93005000A (ru) | Композиция вакцин, способ ее получения, способ исключения иммунной реакции | |
YU33999A (sh) | Metoprolol preparat i postupak za dobijanje istog |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |